Clinical Trials Directory

Trials / Completed

CompletedNCT00002314

A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's Sarcoma

A Phase II Study of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV-Related Kaposi's Sarcoma

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
—
Sponsor
Hoffmann-La Roche · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

To study the effects of Ro 24-7429 on tumor growth in patients with HIV-related Kaposi's sarcoma. To study the safety and tolerance, effects on HIV replication, and immunologic effects of Ro 24-7429 in this patient population. To explore relationships between exposure to Ro 24-7429 and its metabolites with its antitumor and antiviral activities and drug toxicity.

Conditions

Interventions

TypeNameDescription
DRUGRo 24-7429

Timeline

First posted
2001-08-31
Last updated
2005-06-24

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00002314. Inclusion in this directory is not an endorsement.